Saturday, 14 December 2024
  
Login

Australia's most trusted
source of pharma news

Saturday, 14 December 2024
News

Access to patient RWD up for grabs

Posted 28 February 2024 PM

Not-for-profit Crohn's Colitis Cure has opened access to its extensive real-world patient data to assist pharmaceutical companies in regulatory approvals and funding decisions.

"The key to unlocking the potential for personalised, targeted and effective therapies is access to real-world IBD patient data and insights, which will help inform regulatory approvals and speed to access," CCCure CEO, Bill Petch, said.

To see the whole article, please login


Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.